OBJECTIVE: Characterize virologic and immunologic outcomes of INSTI-based antiretroviral therapy (ART) in experienced patients with and without virologic failure. DESIGN: Prospective clinical cohort. METHODS: ART-experienced, INSTI-naive participants in the University of North Carolina Center for AIDS Research HIV Clinical Cohort (UCHCC) initiating an INSTI-containing regimen 2007-2016 were followed from INSTI initiation (baseline) to the earliest of: outcome of interest, loss to follow-up (LTFU, 1 year without clinical visit), or death. Outcomes of interest were virologic failure (first of two consecutive viral loads at least 200 copies/ml more than 2 weeks apart, or one viral load ≥200 before LTFU) and immune recovery (first CD4 ≥500 cells/μl). Patients with baseline viral load at least 50 copies/ml were given 24 weeks before meeting virologic failure criteria. Kaplan-Meier curves and Cox proportional hazards models compared INSTI regimens and patient characteristics. RESULTS: Of 773 patients, 32% were women, 59% African-American, and 42% had a viral load at least 50 copies/ml at INSTI initiation. After 2 years, 5% of patients with baseline viral load less than 50 copies/ml experienced virologic failure, compared with 35% of patients with baseline viral load at least 50 copies/ml (P < 0.01). Among patients with baseline viral load less than 50 copies/ml, dolutegravir/NRTIs was associated with longer time to virologic failure [adjusted hazard ratio (aHR) 0.11, 95% confidence interval (CI) 0.01-0.80], whereas among patients with baseline viral load at least 50 copies/ml, raltegravir/NRTIs was associated with longer time to virologic failure (aHR 0.35, 95% CI 0.18-0.68), both compared with elvitegravir/NRTIs. After 5 years suppressed, irrespective of baseline viral load, 61% of patients experienced immune recovery. CONCLUSION: In this cohort, INSTI-containing regimens led to low virologic failure rates in patients switching ART while suppressed. Viremic patients initiating INSTIs were at high risk of virologic failure during follow-up.
OBJECTIVE: Characterize virologic and immunologic outcomes of INSTI-based antiretroviral therapy (ART) in experienced patients with and without virologic failure. DESIGN: Prospective clinical cohort. METHODS:ART-experienced, INSTI-naive participants in the University of North Carolina Center for AIDS Research HIV Clinical Cohort (UCHCC) initiating an INSTI-containing regimen 2007-2016 were followed from INSTI initiation (baseline) to the earliest of: outcome of interest, loss to follow-up (LTFU, 1 year without clinical visit), or death. Outcomes of interest were virologic failure (first of two consecutive viral loads at least 200 copies/ml more than 2 weeks apart, or one viral load ≥200 before LTFU) and immune recovery (first CD4 ≥500 cells/μl). Patients with baseline viral load at least 50 copies/ml were given 24 weeks before meeting virologic failure criteria. Kaplan-Meier curves and Cox proportional hazards models compared INSTI regimens and patient characteristics. RESULTS: Of 773 patients, 32% were women, 59% African-American, and 42% had a viral load at least 50 copies/ml at INSTI initiation. After 2 years, 5% of patients with baseline viral load less than 50 copies/ml experienced virologic failure, compared with 35% of patients with baseline viral load at least 50 copies/ml (P < 0.01). Among patients with baseline viral load less than 50 copies/ml, dolutegravir/NRTIs was associated with longer time to virologic failure [adjusted hazard ratio (aHR) 0.11, 95% confidence interval (CI) 0.01-0.80], whereas among patients with baseline viral load at least 50 copies/ml, raltegravir/NRTIs was associated with longer time to virologic failure (aHR 0.35, 95% CI 0.18-0.68), both compared with elvitegravir/NRTIs. After 5 years suppressed, irrespective of baseline viral load, 61% of patients experienced immune recovery. CONCLUSION: In this cohort, INSTI-containing regimens led to low virologic failure rates in patients switching ART while suppressed. Viremic patients initiating INSTIs were at high risk of virologic failure during follow-up.
Authors: Joseph J Eron; Jürgen K Rockstroh; Jacques Reynes; Jaime Andrade-Villanueva; Jose Valdez Ramalho-Madruga; Linda-Gail Bekker; Benjamin Young; Christine Katlama; Jose Maria Gatell-Artigas; Jose R Arribas; Mark Nelson; Havilland Campbell; Jing Zhao; Anthony J Rodgers; Matthew L Rizk; Larissa Wenning; Michael D Miller; Daria Hazuda; Mark J DiNubile; Randi Leavitt; Robin Isaacs; Michael N Robertson; Peter Sklar; Bach-Yen Nguyen Journal: Lancet Infect Dis Date: 2011-09-18 Impact factor: 25.071
Authors: Benoît Trottier; Jordan E Lake; Ken Logue; Cynthia Brinson; Lizette Santiago; Clare Brennan; Justin A Koteff; Brian Wynne; Judy Hopking; Catherine Granier; Michael Aboud Journal: Antivir Ther Date: 2017-04-12
Authors: Sej Todd; P Rafferty; E Walker; M Hunter; W W Dinsmore; C M Donnelly; E J McCarty; S P Quah; C R Emerson Journal: Int J STD AIDS Date: 2017-01-24 Impact factor: 1.359
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272
Authors: Amedeo F Capetti; Gaetana Sterrantino; Maria Vittoria Cossu; GianCarlo Orofino; Giorgio Barbarini; Giuseppe V De Socio; Simona Di Giambenedetto; Antonio Di Biagio; Benedetto M Celesia; Barbara Argenteri; Giuliano Rizzardini Journal: PLoS One Date: 2016-10-14 Impact factor: 3.240
Authors: José Antonio Mata-Marín; Ariane Estrella Weiser Smeke; Mariana Rotzinger Rodriguez; Marcelino Chávez-García; Marco Isaac Banda-Lara; Alma Minerva Pérez Rios; Nohemí Nuñez-Rodríguez; Juan Carlos Domínguez-Hermosillo; Alberto Chaparro Sánchez; Irene Juarez-Kasusky; Javier Enrique Cruz Herrera; Jorge Luis Sandoval Ramírez; Jesús Gaytán-Martínez Journal: Drugs R D Date: 2017-03
Authors: Joseph J Eron; Chloe Orkin; Joel Gallant; Jean-Michel Molina; Eugenia Negredo; Andrea Antinori; Anthony Mills; Jacques Reynes; Erika Van Landuyt; Erkki Lathouwers; Veerle Hufkens; John Jezorwski; Simon Vanveggel; Magda Opsomer Journal: AIDS Date: 2018-07-17 Impact factor: 4.177
Authors: Joseph C Gathe; Robin L Hardwicke; Fernando Garcia; Steven Weinheimer; Stanley T Lewis; Robert Brandon Cash Journal: J Acquir Immune Defic Syndr Date: 2021-04-01 Impact factor: 3.771
Authors: Anne K Monroe; Matthew E Levy; Alan E Greenberg; Jeanne C Keruly; Richard D Moore; Michael A Horberg; Paige Kulie; Bernadine S Mohanraj; Princy N Kumar; Amanda D Castel Journal: Open Forum Infect Dis Date: 2021-07-27 Impact factor: 3.835